夏宁邵，中国工程院院士，微生物与生物技术药学专家，厦门大学公共卫生学院/生命科学学院教授，博士生导师。现任国家传染病诊断试剂与疫苗工程技术研究中心主任、传染病疫苗研发全国重点实验室主任、翔安创新实验室主任。长期从事传染病疫苗和诊断试剂的创新与转化应用研究，主持研制并转化上市全球首个戊肝疫苗、首个国产HPV疫苗（二价，获WHO PQ认证）、首个国产九价HPV疫苗、全球首个鼻喷流感病毒载体新冠疫苗、全球首个戊肝抗原尿液检测试剂、全球首个艾滋尿液抗体自检试剂、全球首个P85-Ab鼻咽癌诊断试剂等创新产品。以通讯或共同通讯作者在NEJM、Lancet等高水平期刊发表论文70余篇；以第一完成人获国家技术发明奖二等奖、国家科学技术进步奖二等奖、全国创新争先奖、中国专利奖金奖、求是杰出科技成就集体奖等奖项。

代表性论文：

1. Huang S#, Zhang X#, Su Y#, Zhuang C#, Tang Z#, Huang X, Chen Q, Zhu K, Hu X, Ying D, Liu X, Jiang H, Zang X, Wang Z, Yang C, Liu D, Wang Y, Tang Q, Shen W, Cao H, Pan H, Ge S, Huang Y, Wu T*, Zheng Z*, Zhu F*, Zhang J*, Xia N*. Long-term efficacy of a recombinant hepatitis E vaccine in adults: 10-year results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024;403(10429):813-823.

2. Li T#, Li F#, Guo X#, Hong C#, Yu X#, Wu B, Lian S, Song L, Tang J, Wen S, Gao K, Hao M, Cheng W, Su Y, Zhang S, Huang S, Fang M, Wang Y, Ng M-H, Chen H, Luo W, Ge S*, Zhang J, Xia N*, Ji M*. Anti-Epstein-Barr Virus BNLF2b for Mass Screening of Nasopharyngeal Cancer. The New England Journal of Medicine. 2023;389(9):808-819.

3. Zhang J#, Zhang XF, Huang SJ, Wu T, Hu YM, Wang ZZ, Wang H, Jiang HM, Wang YJ, Yan Q, Guo M, Liu XH, Li JX, Yang CL, Tang Q, Jiang RJ, Pan HR, Li YM, Shih JWK, Ng MH, Zhu FC*, Xia NS*. Long-Term Efficacy of a Hepatitis E Vaccine. The New England Journal of Medicine. 2015;372(10):914-22.

4. Zhu FC#, Zhang J#, Zhang XF, Zhou C, Wang ZZ, Huang SJ, Wang H, Yang CL, Jiang HM, Cai JP, Wang YJ, Ai X, Hu YM, Tang QA, Yao X, Yan QA, Xian YL, Wu T, Li YM, Miao J, Ng MH, Shih JWK, Xia NS*. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet. 2010;376(9744):895-902.

5. Chen X#, Liu X#*, Xu T#, Wang Y#, Wang P, Liu H, Jiang Y, Qin X, Zhang L, Xiong Y, Ding J, Chen Y, Chen F, Ning W, Zeng H, Yang S, Xu L, Zhang T, Yuan Q, Liu C*, Luo W*, Xia N*. Engineered virus-hunter vaccine overcomes HBV immune tolerance. Gut. 2025;gutjnl-2025-335806.

6. Fu R#, Qi RY#, Xiong HL#, Lei X#, Jiang Y#, He JH, Chen F, Zhang L, Qiu DK, Chen YY, Nie MF, Guo XR, Zhu YH, Zhang JL, Yue MX, Cao JL, Wang GS, Que YQ, Fang MJ, Wang YB, Chen YX, Cheng T, Ge SX, Zhang J, Yuan Q*, Zhang TY*, Xia NS*. Combination therapy with oncolytic virus and T cells or mRNA vaccine amplifies antitumor effects. Signal Transduction and Targeted Therapy. 2024;9(1).

7. Qi RY#, Fu R#, Lei X#, He JH#, Jiang Y, Zhang L, Wu YT, Wang SL, Guo XR, Chen F, Nie MF, Yang M, Chen YY, Zeng J, Xu JJ, Xiong HL, Fang MJ, Que YQ, Yao YL, Wang YB, Cao JL, Ye HM, Zhang YL, Zheng ZZ, Cheng T, Zhang J, Lin X*, Yuan Q*, Zhang TY*, Xia NS*. Therapeutic vaccine-induced plasma cell differentiation is defective in the presence of persistently high HBsAg levels. Journal of Hepatology. 2024;80(5).

8. Zhu FC#, Huang SJ#, Liu XH#, Chen Q#, Zhuang CL#, Zhao H#, Han JL#, Jaen AM, Do TH, Peter JG, Dorado AG, Tirador LS, Zabat GMA, Villalobos REM, Gueco GP, Botha LLG, Pertuz SPI, Tan JX, Zhu KX, Quan JL, Lin HY, Huang Y, Jia JZ, Chu XF, Chen JY, Chen YX, Zhang TY*, Su YY*, Li CG*, Ye XZ*, Wu T*, Zhang J*, Xia NS*, Team C-P-S. Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine. 2023;11(12):1075-1088.

9. Zhu FC#, Zhong GH#, Huang WJ#, Chu K, Zhang L, Bi ZF, Zhu KX, Chen Q, Zheng TQ, Zhang ML, Liu S, Xu JB, Pan HX, Sun G, Zheng FZ, Zhang QF, Yi XM, Zhuang SJ, Huang SJ, Pan HR*, Su YY*, Wu T*, Zhang J*, Xia NS*. Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18-26 years in China: a randomised blinded clinical trial. The Lancet Infectious Diseases. 2023；23(11): 1313-1322.

10. Zhao FH#, Wu T#, Hu YM#, Wei LH#, Li MQ#, Huang WJ#, Chen W#, Huang SJ#, Pan QJ, Zhang X, Hong Y, Zhao C, Li Q, Chu K, Jiang YF, Li MZ, Tang J, Li CH, Guo DP, Ke LD, Wu X, Yao XM, Nie JH, Lin BZ, Zhao YQ, Guo M, Zhao J, Zheng FZ, Xu XQ, Su YY, Zhang QF, Sun G, Zhu FC, Li SW, Li YM, Pan HR, Zhang J*, Qiao YL*, Xia NS*. Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial. The Lancet Infectious Diseases. 2022;22(12): 1756-1768.